Wells Fargo raised the firm’s price target on Jazz Pharmaceuticals (JAZZ) to $235 from $170 and keeps an Overweight rating on the shares. The firm sees zanidatamab’s gastroesophageal adenocarcinoma read out supporting it as new standard of care in GEA. Zani’s success in GEA may be a readthrough to breast cancer, and Wells sees an unadjusted peak opportunity of about $3B in both indications. Data is expected in Q1 2026, potentially at ASCO GI, the firm adds.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz Pharmaceuticals’ Promising Pipeline and Strong Trial Results Lead to Buy Rating and Raised Price Objective
- Zymeworks Stock (ZYME) Soars on Positive Results for Cancer Drug Ziihera, Top Analysts Boost Price Targets
- Jazz Pharmaceuticals price target raised to $225 from $185 at Jefferies
- Morning News Wrap-Up: Monday’s Biggest Stock Market Stories!
- Jazz Pharmaceuticals rises 20.6%